{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:24:20Z","timestamp":1784251460898,"version":"3.55.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>In the post-COVID-19 era, the co-circulation of respiratory viruses, including influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), continues to have significant health impacts and presents ongoing public health challenges. Vaccination remains the most effective measure for preventing viral infections. To address the concurrent circulation of these respiratory viruses, extensive efforts have been dedicated to the development of combined vaccines. These vaccines utilize a range of platforms, including mRNA-based vaccines, viral vector vaccines, and subunit vaccines, providing opportunities in addressing multiple pathogens at once. This review delves into the major advancements in the field of combined vaccine research, underscoring the strategic use of various platforms to tackle the simultaneous circulation of respiratory viruses effectively.<\/jats:p>","DOI":"10.3389\/fcimb.2024.1412478","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T04:44:20Z","timestamp":1717562660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines"],"prefix":"10.3389","volume":"14","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.15585\/mmwr.mm7150a4","article-title":"Prevalence of SARS-coV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with influenza - United States, 2021-22 influenza season","volume":"71","author":"Adams","year":"2022","journal-title":"MMWR Morbid. mortal. week. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccines immunother."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01337-22","article-title":"A recombinant VSV-based bivalent vaccine effectively protects against both SARS-coV-2 and influenza A virus infection","volume":"96","author":"Ao","year":"2022","journal-title":"J. virol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"ofac206","DOI":"10.1093\/ofid\/ofac206","article-title":"Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults","volume":"9","author":"August","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/jphp.12353","article-title":"Recombinant protein subunit vaccine synthesis in microbes: a role for yeast","volume":"67","author":"Bill","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060944","article-title":"Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against influenza and SARS-coV-2 viruses","volume":"10","author":"Bommireddy","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1912884","DOI":"10.1080\/19420862.2021.1912884","article-title":"Protective antibodies against human parainfluenza virus type 3 infection","volume":"13","author":"Boonyaratanakornkit","year":"2021","journal-title":"MAbs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01578-21","article-title":"A single vaccine protects against SARS-coV-2 and influenza virus in mice","volume":"96","author":"Cao","year":"2022","journal-title":"J. virol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00689-22","article-title":"A virion-based combination vaccine protects against influenza and SARS-coV-2 disease in mice","volume":"96","author":"Chaparian","year":"2022","journal-title":"J. virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jconrel.2024.01.017","article-title":"Protein subunit vaccines: Promising frontiers against COVID-19","volume":"366","author":"Chavda","year":"2024","journal-title":"J. Control Release."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.scib.2022.05.018","article-title":"A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2","volume":"67","author":"Chen","year":"2022","journal-title":"Sci. Bull. (Beijing)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1542\/hpeds.2022-006613","article-title":"Factors associated with severe illness in patients aged <21 years hospitalized for COVID-19","volume":"12","author":"Choudhary","year":"2022","journal-title":"Hosp Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1093\/cid\/ciz1034","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: A randomized, controlled trial","volume":"71","author":"Cowling","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.681469","article-title":"COVID-19 and influenza co-infection: A systematic review and meta-analysis","volume":"8","author":"Dadashi","year":"2021","journal-title":"Front. Med. (Lausanne)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104776","article-title":"Evaluation of the immune response of a H7N9 candidate vaccine virus derived from the fifth wave A\/Guangdong\/17SF003\/2016","volume":"104776","author":"Dong","year":"2020","journal-title":"Antiviral Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","article-title":"A systematic review of SARS-CoV-2 vaccine candidates","volume":"5","author":"Dong","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/sj.onc.1206459","article-title":"GM-CSF-secreting melanoma vaccines","volume":"22","author":"Dranoff","year":"2003","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1038\/s41598-018-29401-x","article-title":"A VSV-based Zika virus vaccine protects mice from lethal challenge","volume":"8","author":"Emanuel","year":"2018","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.medj.2023.11.001","article-title":"Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus","volume":"5","author":"Guan","year":"2023","journal-title":"Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/COH.0000000000000763","article-title":"New vector and vaccine platforms: mRNA, DNA, viral vectors","volume":"17","author":"Hanke","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.927306","article-title":"A comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jpids\/pix012","article-title":"Clinical features of human metapneumovirus infection in ambulatory children aged 5-13 years","volume":"7","author":"Howard","year":"2018","journal-title":"J. Pediatr. Infect. Dis. Soc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.vaccine.2023.12.084","article-title":"Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection","volume":"42","author":"Huang","year":"2024","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7150\/thno.39827","article-title":"Ferritins as natural and artificial nanozymes for theranostics","volume":"10","author":"Jiang","year":"2020","journal-title":"Theranostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1001\/jama.2020.6266","article-title":"Rates of co-infection between SARS-coV-2 and other respiratory pathogens","volume":"323","author":"Kim","year":"2020","journal-title":"Jama"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.vaccine.2021.11.097","article-title":"African American Research Collaborative CGEahau. Underserved population acceptance of combination influenza-COVID-19 booster vaccines","volume":"40","author":"Lennon","year":"2022","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2231573","DOI":"10.1080\/22221751.2023.2231573","article-title":"Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD","volume":"12","author":"Li","year":"2023","journal-title":"Emerg. Microbes infect."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1347710","article-title":"Influenza and COVID-19 co-infection and prevention effectiveness of vaccination: A mathematical modeling study","volume":"14","author":"Liang","year":"2024","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-0716-1884-4_9","article-title":"Design of replication-competent VSV- and ervebo-vectored vaccines against SARS-coV-2","volume":"2410","author":"Liu","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746447","article-title":"Mosaic hemagglutinin-based whole inactivated virus vaccines induce broad protection against influenza B virus challenge in mice","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/v12090987","article-title":"Attenuated influenza virions expressing the SARS-coV-2 receptor-binding domain induce neutralizing antibodies in mice","volume":"12","author":"Loes","year":"2020","journal-title":"Viruses"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/v15040865","article-title":"COVID-19 and respiratory virus co-infections: A systematic review of the literature","volume":"15","author":"Maltezou","year":"2023","journal-title":"Viruses"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: From beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum. Vaccines immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"442782","DOI":"10.1101\/2021.05.05.442782","article-title":"Combination respiratory vaccine containing recombinant SARS-coV-2 spike and quadrivalent seasonal influenza hemagglutinin nanoparticles with matrix-M adjuvant","author":"Massare","year":"2021"},{"key":"B46","doi-asserted-by":"publisher","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"B47","volume-title":"Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open forum infectious diseases","author":"McLaughlin","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","article-title":"Rates of medically attended RSV among US adults: A systematic review and meta-analysis","volume":"9","author":"McLaughlin","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1586\/erv.09.13","article-title":"IL-12 as an adjuvant for the enhancement of protective humoral immunity","volume":"8","author":"Metzger","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"B51","unstructured":"Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults2023"},{"key":"B52","unstructured":"Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease2023"},{"key":"B53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/14712598.2020.1767062","article-title":"Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity","volume":"20","author":"Moreno-Fierros","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1128\/jvi.69.11.6678-6686.1995","article-title":"Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus","volume":"69","author":"Muster","year":"1995","journal-title":"J. Virol."},{"key":"B56","unstructured":"Initial Results from Novavax\u2019 COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine2022"},{"key":"B57","unstructured":"Respiratory Syncytial Virus (RSV) disease2019"},{"key":"B58","unstructured":"WHO statement on reported clusters of respiratory illness in children in northern China2023"},{"key":"B59","unstructured":"WHO Coronavirus (COVID-19) Dashboard2024"},{"key":"B60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"New Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.15585\/mmwr.mm7150a4","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta biomater."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl. J. Med."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411445","article-title":"IgGkappa signal peptide enhances the efficacy of an influenza vector vaccine against respiratory syncytial virus infection in mice","volume":"24","author":"Pulkina","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","article-title":"Development of mRNA vaccines against respiratory syncytial virus (RSV)","volume":"68","author":"Qiu","year":"2022","journal-title":"Cytokine Growth Fact. Rev."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J. Clin. Invest."},{"key":"B67","doi-asserted-by":"publisher","first-page":"566914","DOI":"10.1101\/2023.11.15.566914","article-title":"mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge","volume":"19","author":"Reneer","year":"2023","journal-title":"plos one"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"B69","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"B70","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e28572","DOI":"10.1002\/jmv.28572","article-title":"mRNA vaccines: The future of prevention of viral infections","volume":"95","author":"Rzymski","year":"2023","journal-title":"J. Med. Virol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.chom.2021.02.002","article-title":"Virus vaccines: proteins prefer prolines","volume":"29","author":"Sanders","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae035","article-title":"Safety, tolerability and immunogenicity of a mRNA-based RSV vaccine in healthy young adults in a phase 1 clinical trial","author":"Shaw","year":"2024","journal-title":"J. Infect. Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"104297","DOI":"10.1016\/j.ebiom.2022.104297","article-title":"A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core","volume":"85","author":"Shi","year":"2022","journal-title":"EBioMedicine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/ije\/dyab081","article-title":"Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design","volume":"50","author":"Stowe","year":"2021","journal-title":"Int. J. Epidemiol."},{"key":"B76","first-page":"3155","article-title":"Expert recommendations for the prevention and control of pediatric respiratory syncytial virus infections in China (2023 edition)","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902515","article-title":"A single vaccination of chimeric bivalent virus-like particle vaccine confers protection against H9N2 and H3N2 avian influenza in commercial broilers and allows a strategy of differentiating infected from vaccinated animals","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.virol.2022.09.009","article-title":"SARS-CoV-2 and influenza co-infection: A cross-sectional study in central Missouri during the 2021-2022 influenza season","volume":"576","author":"Tang","year":"2022","journal-title":"Virology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4020012","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines (Basel)."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00135","article-title":"Broadly protective strategies against influenza viruses: universal vaccines and therapeutics","volume":"11","author":"Vogel","year":"2020","journal-title":"Front. Microbiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4100","article-title":"A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00667-20","article-title":"L226Q mutation on influenza H7N9 virus hemagglutinin increases receptor-binding avidity and leads to biased antigenicity evaluation","volume":"94","author":"Wang","year":"2020","journal-title":"J. Virol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.05.583547","article-title":"A 10-valent composite mRNA vaccine against both influenza and COVID-19","author":"Wang","year":"2024"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s00216-021-03806-6","article-title":"Antigenic characterization of influenza and SARS-CoV-2 viruses","volume":"414","author":"Wang","year":"2022","journal-title":"Anal. Bioanal. Chem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.antiviral.2017.03.029","article-title":"A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice","volume":"143","author":"Wang","year":"2017","journal-title":"Antiviral Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3201\/eid3004.231226","article-title":"Seroprevalence of avian influenza A (H5N6) virus infection, Guangdong province, China, 2022","volume":"30","author":"Wang","year":"2024","journal-title":"Emerging Infectious Diseases"},{"key":"B88","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/QCO.0000000000000948","article-title":"mRNA vaccines against respiratory viruses","volume":"36","author":"Whitaker","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/v15071440","article-title":"Recent developments in human papillomavirus (HPV) vaccinology","volume":"15","author":"Williamson","year":"2023","journal-title":"Viruses"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ymthe.2024.02.011","article-title":"A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections","volume":"32","author":"Wu","year":"2024","journal-title":"Mol. Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijid.2023.08.021","article-title":"Prevalence and associated outcomes of coinfection between SARS-CoV-2 and influenza: a systematic review and meta-analysis","volume":"136","author":"Yan","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41541-022-00478-w","article-title":"Rational development of a combined mRNA vaccine against COVID-19 and influenza","volume":"7","author":"Ye","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B93","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1038\/s41467-023-39560-9","article-title":"Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29479","article-title":"A subunit-based influenza\/SARS-CoV-2 Omicron combined vaccine induced potent protective immunity in BALB\/c mice","volume":"96","author":"Zhang","year":"2024","journal-title":"J. Med. virol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2213-2600(23)00349-1","article-title":"Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Zhu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S2213-2600(22)00131-X","article-title":"Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"10","author":"Zhu","year":"2022","journal-title":"Lancet Respir. Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1412478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T09:59:46Z","timestamp":1721383186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1412478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":97,"alternative-id":["10.3389\/fcimb.2024.1412478"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1412478","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"article-number":"1412478"}}